Compare · TNYA vs TPST
TNYA vs TPST
Side-by-side comparison of Tenaya Therapeutics Inc. (TNYA) and Tempest Therapeutics Inc. (TPST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. TNYA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while TPST focuses on Biotechnology: Pharmaceutical Preparations.
- TNYA is the larger of the two at $177.3M, about 11.5x TPST ($15.4M).
- Over the past year, TNYA is down 7.9% and TPST is down 83.4% - TNYA leads by 75.4 points.
- TPST has been more active in the news (9 items in the past 4 weeks vs 6 for TNYA).
- Both have 7 recent analyst ratings on file.
- Company
- Tenaya Therapeutics Inc.
- Tempest Therapeutics Inc.
- Price
- $0.81-3.66%
- $1.05+7.64%
- Market cap
- $177.3M
- $15.4M
- 1M return
- +15.75%
- -15.94%
- 1Y return
- -7.94%
- -83.37%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 9
- Recent ratings
- 7
- 7
Tenaya Therapeutics Inc.
Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.
Tempest Therapeutics Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.
Latest TNYA
- SEC Form 3 filed by new insider Hyllengren Eric J
- SEC Form 4 filed by Chief Financial Officer Hyllengren Eric J
- Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Tenaya Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Tenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
- Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
- Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
- SEC Form 4 filed by Director Williams R Sanders
- SEC Form 4 filed by Director Walsh Jeffrey T.
Latest TPST
- SEC Form DEF 14A filed by Tempest Therapeutics Inc.
- Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
- SEC Form 424B3 filed by Tempest Therapeutics Inc.
- SEC Form EFFECT filed by Tempest Therapeutics Inc.
- SEC Form PRE 14A filed by Tempest Therapeutics Inc.
- SEC Form S-3 filed by Tempest Therapeutics Inc.
- CEO and President Angel Matthew bought $500,001 worth of shares (231,482 units at $2.16) (SEC Form 4)
- SEC Form 8-K filed by Tempest Therapeutics Inc.
- SEC Form D filed by Tempest Therapeutics Inc.
- SEC Form 4 filed by Director Yee John D.